myelogenous leukemia (relapse /refractory)
Conditions
Interventions
experimental group:FBMA
Sponsors
Soochow Hopes Hematonosis Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients with refractory/relapsed acute leukemia diagnosed by bone marrow morphology, immunology, and genetics; 2. Those who have received allogeneic hematopoietic stem cell transplantation (including HLA-matched or incompletely matched allogeneic hematopoietic stem cell transplantation and transplantation from unrelated donors); 3. Aged 18 to 70 years, regardless of gender; 4. The Eastern Cooperative Oncology Group's physical status assessment (ECOG-PS) is 0-2 points; 5. The informed consent form must be signed before the start of the research procedure, and the patient or his immediate family members must sign the informed consent form; considering the patients condition, if the patients own signature is not conducive to the treatment of the condition, the legal guardian or the patients immediate family member shall sign the informed consent form .
Exclusion criteria
Exclusion criteria: 1. Have a history of tumor and have received any treatment for this tumor within the past 3 years; Except for superficial bladder cancer, basal cell or squamous cell carcinoma of the skin, cervical intraepithelial neoplasia (CIN) or prostate intraepithelial neoplasia (PIN); 2. Known positive for HIV or active hepatitis C virus serology; 3. Suffering from mental disorders or other conditions and unable to cooperate with the requirements of research treatment and monitoring; 4. Pregnant patients or patients who cannot take appropriate contraceptive measures during treatment; 5. Received hematopoietic stem cell transplantation within the past 1 year; 6. Active heart disease, defined as one or more of the following: (1) A history of uncontrolled or symptomatic angina pectoris; (2) Myocardial infarction less than 6 months after the entry into the study; (3) A history of arrhythmia requiring drug treatment or severe clinical symptoms; (4) Uncontrolled or symptomatic congestive heart failure (> NYHA class 2); (5) The ejection fraction was lower than the lower limit of the normal range. 7. Those who are deemed unsuitable for inclusion by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relapse-free surviva; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival time;relapsed rate;Transplant-related mortality; | — |
Countries
China
Contacts
Public ContactWu Xiaojin
Soochow Hopes Hematonosis Hospital
Outcome results
None listed